Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion

Ophthalmologica

Volumn 212, Issue 6, 1998, Pages 394-398

  Hattenbach, Lars Olof ^a   Steinkamp, Gerd ^a   Scharrer, Inge ^a   Ohrloff, Christian ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Activator; Frontloading fibrinolytic therapy; Haemorrhagic retinopathy; Recombinant tissue plasminogen; Retinal capillary non perfusion

Indexed keywords

ALTEPLASE; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CAPILLARY FLOW; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; FIBRINOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; RETINA BLOOD FLOW; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; FIBRINOLYTIC AGENTS; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; ISCHEMIA; MIDDLE AGED; RECOMBINANT PROTEINS; RETINAL VEIN OCCLUSION; RETINAL VESSELS; TISSUE PLASMINOGEN ACTIVATOR; VISUAL ACUITY;

EID: 0031716493     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000027374     Document Type: Article

References (29)

1. Hayreh SS: Classification of central retinal vein occlusion. Am Acad Ophthalmol 1983;90:458-474.
2. Hayreh SS: Ocular neovascularization with retinal vascular occlusion. Ophthalmology 1983; 90:488-506.
3. Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C: The natural course of central retinal vein occlusion. Am J Ophthalmol 1990;110: 118-123.
4. Central Vein Occlusion Study Group: Central vein occlusion study of photocoagulation therapy: Baseline findings. Online J Curr Clin Trials 1993 Oct 14, Doc No 95.
5. Peters J, Mackensen D, Meyer-Schwickerath G: Photokoagulation bei retinalen Astvenenverschlüssen. Klin Monatsbl Augenheilkd 1981;179:257-261.
6. Hansen LL, Wiek J, Wiederholt M: A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 1989; 73:895-899.
7. Wolf S, Arend B, Bertram B, Schulte K, Kaufhold F, Teping C, Reim M: Hämodilution bei Patienten mit Zentralvenenthrombose der Retina. Fortschr Ophthalmol 1991;88:35-43.
8. Kohner EM, Pettit JE, Hamilton AM: Streptokinase in central retinal vein occlusion: A controlled clinical trial. Br Med J 1976;i:550-553.
9. Kreutzer A, Brunner R, Schäfer H-J, Sickel W, Auel H, Hossmann V: Lysetherapie mit rt-PA bei Patienten mit Stamm- oder Zentralvenenocclusion der Retina. Fortschr Ophthalmol 1988; 85:511-513.
10. Reim M, Bertram B, Wolf S: Behandlungsversuche der Zentralvenenthrombose der Netzhaut mit Plasminogen-Aktivator (rt-PA). Klin Wochenschr 1988;66:143-149.
11. Sloan M, Gore JM: Ischemic stroke and intracranial haemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis. Am J Cardiol 1992;69:21A-38A.
12. Kase CS, O'Neal AM, Fisher M, Girgis GN, Ordia JL: Intracranial haemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Intern Med 1990;112:17-21.
13. Gore JM, Sloan M, Price TR, Randall AMY, Bovill E, Collen D, Forman S, Knatterud GL, Sopko G, Terrin ML, and the TIMI Investigators: Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Thrombolysis in Myocardial Infarction: Phase II, pilot and clinical trial. Circulation 1991;83:448-459.
14. Brott TG, Haley EC Jr, Levy DE: Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-640.
15. Haley EC Jr, Levy DE, Brott TG: Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-645.
16. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
17. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329: 1615-1622.
18. Smith P, Green WR, Miller NR, Terry JM: Clinicopathologic case report of bilateral central retinal vein occlusion in Reye's syndrome. Arch Ophthalmol 1980;98:1256-1260.
19. Green WR, Chan CC, Hutchins GM, Terry JM: Central retinal vein occlusion: A prospective histopathologic study of 29 eyes in 28 cases. Retina 1981;1:27-55.
20. Metzler de Höhmann U: Fibrinolyse und Antikoagulantientherapie bei retinalen Venenverschlüssen. Marburg, Medizinische Verlagsgesellschaft, 1977.
21. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group: ISIS-3: A randomised comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected myocardial infarction. Lancet 1993;339:753-770.
22. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
23. Chesebro JH, Knatterud G, Roberts R: Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation 1987;76:142-154.
24. Verstraete M, Bernard R, Bory M: Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: Report from the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Lancet 1985;i:842-847.
25. Anderson JL, Karagounis L, Allan A, Bradford MJ, Menlove RL, Pryor TA: Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991;68:166-170.
26. Johannessen K-A, Nordrehaug JE, von der Lippe G, Vollset SE: Risk factors for embolization in patients with left ventricular thrombi and acute myocardial infarction. Br Heart J 1988; 60:104-110.
27. O'Connor CM, Aldrich H, Massey EW, Uglietta J, Mark DB, Califf RW: Intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Clinical characteristics and in hospital outcome (abstract). J Am Coll Cardiol 1990;15 (suppl):213A.
28. Chaitman BR, Thompson B, Wittry MD, Stump D, Hamilton WP, Hillis LD, Dwyer JG, Solomon RE, Knatterud GL for the TIMI Investigators: The use of tissue plasminogen activator for acute myocardial infarction in the elderly: Results from the Thrombolysis in Myocardial Infarction Phase I Open-Label Studies, and the Thrombolysis in Myocardial Infarction Phase II Pilot Study. J Am Coll Cardiol 1989;14:1159-1165.
29. Bertram B, Wolf S, Fisches H, Schulte K, Hoberg A, Reim M: Lysebehandlung bei retinalen Arterienverschlüssen mit Plasminogen-Aktivator. Klin Monatsbl Augenheilkd 1991;198:295-300.